Natispray (Glyceryl Trinitrate Solution)

Glyceryl trinitrate is a nitric‑oxide donor. After sublingual absorption it is converted to nitric oxide, which activates guanylate cyclase in vascular smooth‑muscle cells, increasing cyclic GMP levels. Elevated cGMP causes relaxation of veins and arteries, decreasing preload and afterload, and dilating coronary arteries, thereby lowering myocardial oxygen consumption.

The specific dose of Natispray is determined by the prescribing clinician based on the individual’s clinical condition, severity of angina, and response to therapy. Typically a single spray provides a defined amount of glyceryl trinitrate, and additional doses may be administered as directed by a healthcare professional. Patients should follow the prescriber’s instructions precisely.

The safety of glyceryl trinitrate in pregnancy and lactation has not been definitively established, and the product is classified as pregnancy category unknown. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To request Natispray, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials. The sales team then provides pricing, availability, shipping details and any necessary import documentation.

Natispray delivers glyceryl trinitrate rapidly via the sublingual route, offering quicker onset of relief compared with oral nitrates or beta‑blockers. Unlike long‑acting oral formulations, the spray is intended for acute episodes and prophylaxis, and its vasodilatory effect is mediated through nitric‑oxide release, whereas other classes such as calcium‑channel blockers act by different mechanisms.

Natispray should be stored at room temperature below 25 °C. Keep the container tightly closed, protect it from moisture, heat and direct sunlight, and store it in its original packaging until use. Do not expose the spray to freezing temperatures, as this may affect the stability of the solution.

Natispray is administered sublingually. The patient removes the cap, places the spray nozzle under the tongue, and actuates the device to deliver a single spray. The medication is absorbed through the oral mucosa, providing rapid onset of action. Patients should remain seated or lying down after administration to reduce the risk of dizziness or fainting.

The most serious risks include severe hypotension, syncope, and rare cases of methemoglobinemia, which can be life‑threatening if not recognized promptly. Patients should be monitored for signs of profound blood‑pressure drop, loss of consciousness, or cyanosis, and medical attention should be sought immediately if these occur.

Natispray is contraindicated in patients with known hypersensitivity to glyceryl trinitrate or other organic nitrates, those who have taken phosphodiesterase‑5 inhibitors within the previous 24‑48 hours, and individuals with severe aortic stenosis, hypertrophic cardiomyopathy, or uncontrolled hypotension. These conditions increase the risk of dangerous drops in blood pressure.